Skip to main content

Table 1 Characteristics of study participants

From: Relationship between key continuous glucose monitoring-derived metrics and specific cognitive domains in patients with type 2 diabetes mellitus

Variable

Total

(n = 96)

Without hypoglycemia

(n = 52)

With hypoglycemia

(n = 44)

P values

Male, n (%)

57 (59.38)

27 (51.92)

30 (68.18)

0.106

Age (years)

61.40 ± 7.84

61.06 ± 8.57

61.80 ± 6.96

0.648

Education: junior college degree or above, n (%)

41 (42.71)

20 (38.46)

21 (47.73)

0.087

Diabetes duration (years)

13.05 ± 7.81

13.00 ± 7.69

13.11 ± 8.03

0.944

SBP (mmHg)

133.89 ± 13.88

133.88 ± 14.37

133.89 ± 13.44

1.000

DBP (mmHg)

80.68 ± 9.07

81.15 ± 8.61

80.11 ± 9.66

0.578

BMI (kg/m2)

26.11 ± 3.91

26.64 ± 4.15

25.48 ± 3.56

0.150

Total cholesterol (mmol/L)

4.84 ± 1.09

4.90 ± 1.12

4.76 ± 1.06

0.510

Triglycerides (mmol/L)

1.39 (0.98, 2.19)

1.68 (0.93, 2.46)

1.31 (1.01, 1.85)

0.184

HDL (mmol/L)

1.18 (1.03, 1.39)

1.19 (1.04, 1.40)

1.16 (1.01, 1.32)

0.476

LDL (mmol/L)

3.00 ± 0.79

3.03 ± 0.76

2.97 ± 0.83

0.753

HbA1c (%)

7.85 (7.20, 8.70)

8.15 (7.43, 9.08)

7.45 (6.70, 8.18)

< 0.001

FPG (mmol/L)

8.50 (7.13, 10.47)

8.83 (7.69, 11.58)

7.91 (6.21, 9.44)

0.005

TIR (%)

61.66 ± 27.76

52.34 ± 31.25

72.68 ± 17.73

< 0.001

TAR10.1–13.9 mmol/L (%)

20.50 (11.26, 33.27)

29.30 (16.75, 41.75)

16.08 (6.00, 21.05)

< 0.001

TAR> 13.9 mmol/L (%)

2.91 (0.00, 18.00)

8.60 (0.09, 28.86)

1.05 (0.00, 6.81)

0.002

SD (mmol/L)

2.60 ± 0.84

2.59 ± 0.73

2.61 ± 0.96

0.883

GRI

34.32 (20.00, 64.60)

39.75 (18.18, 83.30)

29.38(20.98, 47.03)

0.158

MG (mmol/L)

9.27 ± 2.76

10.50 ± 2.88

7.81 ± 1.71

< 0.001

CV (%)

26.50 (23.65, 33.00)

24.77 (21.61, 27.02)

32.15 (26.85, 37.50)

< 0.001

MAGE (mmol/L)

5.66 (4.21, 7.00)

5.80 (4.36, 6.81)

5.24 (3.98, 7.66)

0.903

Use antidiabetes agents

Insulin, n (%)

47 (48.96)

27 (51.92)

20 (45.45)

0.528

Sulfonylurea, n (%)

19 (19.79)

11 (21.15)

8 (18.18)

0.716

Biguanides, n (%)

67 (69.79)

38 (73.08)

29 (65.91)

0.446

α-glucosidase inhibitors, n (%)

51 (53.13)

27 (51.92)

24 (54.55)

0.798

Dipeptidyl peptidase 4 inhibitors, n (%)

10 (10.42)

6 (11.54)

4 (9.09)

0.696

Glucagon-like peptide 1 receptor agonists, n (%)

10 (10.42)

4 (7.69)

6 (13.64)

0.342

Sodium–glucose cotransporter 2 inhibitors, n (%)

5 (5.21)

3 (5.77)

2 (4.55)

0.788

  1. Data are presented as means ± standard deviations or medians (interquartile ranges) for continuous variables, and numbers (percentages) for categorical variables. A two-tailed value of P < 0.05 was considered as statistically significant.
  2. SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; TIR, time in range; TAR, time above range; SD, standard deviation; GRI, glycemia risk index; MG, mean glucose; CV, coefficient of variation; MAGE, mean amplitude of glycemic excursions
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us